Senior scientist with a broad range of experience in applying chemistry to solve biological problems and expertise in drug design. Formal background in synthetic organic chemistry currently working in the bioconjugation and related modalities space. Previous work in neuroscience culminated in an assortment of patented intellectual property and a drug (ABX-002, via Autobahn Therapeutics) in a Phase II clinical trial for major depressive disorder (clinical trial identifier: NCT06633016). More broadly, my main scientific interests include novel drug design, innovative modalities for drug delivery, and regenerative medicine.